ESR1 and prostate cancer: To evaluate the anticancer activity of the 13 newly synthesized compounds, we screened their activities at a concentration of 50 μM against seven cancer cell lines, including breast cancer (positive [MCF-7] and negative [MDA-MB-231] for estrogen receptor expression), tongue carcinoma (SAS), prostate cancer (PC-3), colorectal cancer (HCT-116) and liver cancer (HuH-7 and HepG2) cell lines.